Abstract
To evaluate the pharmacological properties of cilostazol (CLZ), we examined its intraocular pressure (IOP) -lowering effect. CLZ is an inhibitor of Type III phosphodiesterase that increases intracellular cyclic AMP levels by restraining platelet aggregation, and has a potential protective effect against atherosclerosis. We attempted to apply it for use as an anti-glaucoma agent; however, the application of CLZ in the ophthalmic field is limited due to its poor water solubility. We attempted to enhance CLZ solubility using 2-hydroxypropyl-beta-cyclodextrin (HPbetaCD). The solubility of CLZ increased with increasing HPbetaCD concentrations, and 0.05% CLZ was dissolved in 10% HPbetaCD. Moreover, fine particle suspension of 0.5% CLZ in 5% HPbetaCD (soluble CLZ: ca. 0.027%) were prepared using a Microfluidizer, an impact-type emulsifying comminution device. In an in vitro transcorneal penetration experiment through the rabbit cornea, the CLZ penetration rate was dependent on the CLZ content of the solutions and suspensions. When a 0.05% CLZ ophthalmic solution was instilled into a rabbit eye, the absorption rate constant for CLZ into an aqueous humor was 0.0059+/-0.001 min(-1), and the elimination rate constant was 0.048+/-0.024 min...Continue Reading
References
Nov 1, 1978·Archives of Ophthalmology·R L Coakes, R F Brubaker
Apr 1, 1992·Archives of Ophthalmology·E A LippaA Ringvold
Aug 7, 1992·Cell·A J RidleyA Hall
Nov 1, 1991·Archives of Ophthalmology·T OshikaI Azuma
Feb 1, 1989·Chemical & Pharmaceutical Bulletin·T OgisoY Yamamoto
Sep 1, 1989·Experimental Eye Research·B T Gabelt, P L Kaufman
Oct 1, 1989·Experimental Eye Research·O Mäepea, A Bill
Apr 1, 1980·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·S IwataH Ogino
Dec 1, 1995·Archives of Ophthalmology·C B TorisM E Yablonski
Jun 1, 1995·Trends in Biochemical Sciences·Y TakaiH Nakanishi
Aug 1, 1995·Experimental Eye Research·M WiederholtA Lepple-Wienhues
Mar 1, 1995·Ophthalmology·C B TorisM E Yablonski
Feb 1, 1994·Current Opinion in Genetics & Development·C Nobes, A Hall
Apr 15, 1993·The New England Journal of Medicine·H A Quigley
Aug 26, 1998·Pharmaceutical Research·P Saarinen-SavolainenA Urtti
Jan 7, 1998·Current Opinion in Ophthalmology·R M Kershner
Jul 23, 1999·Survey of Ophthalmology·P L KaufmanM Cynader
Oct 8, 2003·Current Pharmaceutical Design·Junichi KambayashiFrank Czerwiec
Dec 30, 2004·Investigative Ophthalmology & Visual Science·Li GuoM Francesca Cordeiro
Dec 7, 2007·Investigative Ophthalmology & Visual Science·Megumi HonjoMakoto Araie
Apr 9, 2008·Neuroscience Letters·Ryosuke KashimotoOsamu Mimura
Apr 26, 2008·Investigative Ophthalmology & Visual Science·Maria de la FuenteMaria J Alonso
Dec 20, 2008·Journal of Pharmaceutical and Biomedical Analysis·Marzia CirriPaola Mura
Jul 3, 2009·Biological & Pharmaceutical Bulletin·Masazumi YamaguchiKakuji Tojo
Citations
Jan 7, 2014·Biological & Pharmaceutical Bulletin·Noriaki Nagai, Yoshimasa Ito
Nov 6, 2015·International Journal of Molecular Sciences·Meng MengDaojun Cheng
Jul 3, 2015·Journal of Oleo Science·Noriaki NagaiYoshikazu Shimomura
Dec 23, 2015·International Journal of Molecular Sciences·Noriaki NagaiAtsufumi Kawabata
Dec 17, 2015·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Venkata Kashyap Yellepeddi, Srinath Palakurthi
Jan 15, 2014·Journal of Oleo Science·Noriaki NagaiYoshikazu Shimomura
Mar 7, 2014·Toxicology·Noriaki NagaiYoshikazu Shimomura
Jan 18, 2018·International Journal of Molecular Sciences·Noriaki NagaiYoshikazu Shimomura
Sep 3, 2017·British Journal of Pharmacology·Sahar AwwadAlastair Lockwood
Nov 15, 2017·Drug Delivery and Translational Research·María Sebastián-MorellóAlicia López-Castellano
Sep 16, 2020·Pharmaceutics·María Sebastián-MorellóAlicia López-Castellano
Jun 3, 2020·Journal of Medicinal Chemistry·Kuei-Ju ChengJing-Ping Liou